Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Liraglutide may reduce stroke recurrence in type 2 diabetes patients
Última actualización 6 de julio de 2026
Key finding
Hazard ratio, 0.56 (95% CI, 0.34-0.91); P = .02
This study investigated the effects of liraglutide on stroke recurrence in patients with type 2 diabetes, finding a lower rate of recurrence compared to the control group.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda este estudio en tu Evidence Tracker para encontrarlo facilmente cuando lo necesites.
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study investigated the effects of liraglutide on stroke recurrence in patients with type 2 diabetes, finding a lower rate of recurrence compared to the control group.
Clinical relevance
The findings suggest that liraglutide not only aids in diabetes management but may also play a crucial role in reducing the risk of stroke recurrence. This is significant for clinicians as it highlights the potential of liraglutide to improve patient outcomes in a population at high risk for vascular events.
Keep in mind
The study's sample size may limit the generalizability of the findings. The follow-up period of 90 days may not capture long-term outcomes. Potential confounding factors were not fully controlled for in the analysis.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Huili Z, Bin Y, Longyan L, et al. Liraglutide and Stroke Recurrence in Patients with Type 2 Diabetes. JAMA Internal Medicine. 2025;186(1):46-54. doi:10.1001/jamainternmed.2025.5684
Efectos Principales
Liraglutide reduced stroke recurrence to 7.9% compared to 13.8% in the control group (p=0.02).
The incidence of ischemic stroke was lower in the liraglutide group at 7.6% versus 13.5% in controls (p=0.02).
A higher proportion of patients achieved a modified Rankin Scale score of ≤ 1 in the liraglutide group (87.3%) compared to controls (77.8%).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Liraglutide and Acute pancreatitis, All-cause mortality, Gastrointestinal disorders incidence, and 8 more.
This study contributes evidence to
Primary intervention
Liraglutide
Primary outcomes
- Acute pancreatitis
- All-cause mortality
- Gastrointestinal disorders incidence
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
11
Evidence pairs
11
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
3
Related topics
11
Evidence pairs
98
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 11 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and Cardiovascular Outcomes
Evidencia relacionada
Relación de evidencia
GLP-1 Receptor Agonists and Hypoglycemia
Seguir evidencia
Relación de evidencia
GLP-1 Receptor Agonists and Gastrointestinal Adverse Events
Seguir evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerGastrointestinal disorders incidence
Liraglutide → Gastrointestinal disorders incidence
Liraglutide → Gastrointestinal disorders incidence
Evidence Intelligence™
- ImpactScore™
- 38
- Slightly Negative
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerIncidence of vascular events within 90 days
Liraglutide → Incidence of vascular events within 90 days
Liraglutide → Incidence of vascular events within 90 days
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerModified Rankin Scale score ≤ 1
Liraglutide → Modified Rankin Scale score ≤ 1
Liraglutide → Modified Rankin Scale score ≤ 1
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerSymptomatic intracranial hemorrhage
Liraglutide → Symptomatic intracranial hemorrhage
Liraglutide → Symptomatic intracranial hemorrhage
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerBuild your personal Evidence Workspace
Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Today's Activity
Your Evidence Workspace
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
La Evidencia Sugiere
- Stroke recurrence was reduced by 0.56 events with liraglutide (p=0.02).
- Ischemic stroke incidence decreased by 0.55 events in the liraglutide group (p=0.02).
- Patients on liraglutide had 1.95 times higher odds of achieving better recovery outcomes.
A quién se aplica
- Adults aged 40-75 with type 2 diabetes.
- Patients with a history of stroke or transient ischemic attack.
Tener en Cuenta
- Results may not apply to younger populations or those without diabetes.
- The study did not include patients with acute pancreatitis.
- Findings are based on a short follow-up period, necessitating further research.
Entre Líneas
- The study's sample size may limit the generalizability of the findings.
- The follow-up period of 90 days may not capture long-term outcomes.
- Potential confounding factors were not fully controlled for in the analysis.
Save this study
Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.
Today's Activity
Your Evidence Workspace
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Gastrointestinal Adverse Events, GLP-1 Receptor Agonists and Acute pancreatitis.
Relaciones de evidencia relacionadas
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Detailed evidenceEvidence Intelligence™
- ImpactScore™
- 38
- Slightly Negative
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
View evidenceMedications
Detailed evidenceGLP-1 Receptor Agonists → Acute pancreatitis
Medications
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Gastrointestinal Adverse Events Evidence Hub
All studies measuring Gastrointestinal Adverse Events
2 studies
outcome_hubMeasures Gastrointestinal Adverse Events as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
2 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Acute pancreatitis Evidence Hub
All studies measuring Acute pancreatitis
1 studies
outcome_hubMeasures Acute pancreatitis as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en el archivo de evidencia
Jump to pre-filtered views in the evidence archive.
All studies on Liraglutide and Gastrointestinal disorders incidence
Intervention: LiraglutideOutcome: Gastrointestinal disorders incidence
2 results
All studies on Liraglutide and Acute pancreatitis
Intervention: LiraglutideOutcome: Acute pancreatitis
1 results
All studies on Liraglutide
Intervention: Liraglutide
2 results
All studies measuring Gastrointestinal disorders incidence
Outcome: Gastrointestinal disorders incidence
2 results
All studies measuring Acute pancreatitis
Outcome: Acute pancreatitis
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists improve cardiovascular outcomes?
Strong Evidence
GLP-1 Receptor Agonists may improve Cardiovascular Outcomes.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
All-cause mortality
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 11 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect hypoglycemia?
Strong Evidence
GLP-1 Receptor Agonists may improve Hypoglycemia.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Hypoglycemia events
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 12 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect gastrointestinal adverse events?
Strong Evidence
GLP-1 Receptor Agonists may worsen Gastrointestinal Adverse Events or be associated with harm.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Gastrointestinal disorders incidence
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | weak negative | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 5 supporting studies and existing graph evidence signals.
Limitations
- Population details are unavailable.
Does Liraglutide improve incidence of vascular events within 90 days?
Emerging Evidence
Liraglutide appears to improve Incidence of vascular events within 90 days.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Incidence of vascular events within 90 days
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.